<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006381</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068255</org_study_id>
    <secondary_id>MSKCC-00078</secondary_id>
    <secondary_id>NCI-G00-1869</secondary_id>
    <nct_id>NCT00006381</nct_id>
  </id_info>
  <brief_title>Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Study of Celecoxib in HER-2/Neu Overexpressing Metastatic Breast Cancer Patients Who Have Failed Recombinant Humanized Anti-p 185HER Monoclonal Antibody Trastuzumab (HERCEPTIN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Celecoxib may be effective in preventing the further development of cancer.&#xD;
      Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or&#xD;
      deliver tumor-killing substances to them without harming normal cells. Combining trastuzumab&#xD;
      with celecoxib may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining celecoxib and trastuzumab in&#xD;
      treating women who have metastatic breast cancer that has not responded to previous&#xD;
      trastuzumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of celecoxib and trastuzumab (Herceptin) in women with&#xD;
           HER2/neu-overexpressing metastatic breast cancer that is refractory to prior&#xD;
           trastuzumab.&#xD;
&#xD;
        -  Determine the safety of celecoxib in these patients.&#xD;
&#xD;
      OUTLINE: At least 3 weeks after the last dose of prior chemotherapy, patients receive oral&#xD;
      celecoxib twice daily. Patients continue or restart trastuzumab (Herceptin) IV over 30-90&#xD;
      minutes weekly or every 3 weeks. Treatment continues in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within&#xD;
      approximately 9 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven metastatic breast cancer&#xD;
&#xD;
               -  HER2/neu-positive (overexpressing) tumor tissue&#xD;
&#xD;
          -  Failed prior trastuzumab (Herceptin) therapy with or without chemotherapy&#xD;
&#xD;
          -  Resected stage IV disease allowed if evidence of disease&#xD;
&#xD;
          -  Bidimensionally measurable or evaluable disease&#xD;
&#xD;
               -  No lesions in previously irradiated field except nonbone lesions progressive&#xD;
                  after radiotherapy&#xD;
&#xD;
               -  No pleural effusions&#xD;
&#xD;
               -  No blastic or mixed bony metastases&#xD;
&#xD;
               -  No palpable abdominal masses&#xD;
&#xD;
          -  No leptomeningeal disease&#xD;
&#xD;
          -  Brain metastases allowed if:&#xD;
&#xD;
               -  No concurrent use of steroids&#xD;
&#xD;
               -  At least 3 months since prior brain irradiation&#xD;
&#xD;
               -  No evidence of progression of metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8.0 g/dL&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  AST/ALT no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF at least 50%&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  No other prior malignancy within the past 5 years except adequately treated carcinoma&#xD;
             in situ of the cervix or nonmelanoma skin cancer&#xD;
&#xD;
          -  No other serious medical illness&#xD;
&#xD;
          -  No severe infection&#xD;
&#xD;
          -  No severe malnutrition&#xD;
&#xD;
          -  No prior allergic reactions to sulfonamides or celecoxib&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior trastuzumab (Herceptin) for breast cancer allowed, either as&#xD;
             adjuvant/neoadjuvant or for metastatic disease&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  Prior cytotoxic therapy for breast cancer allowed, either as adjuvant/neoadjuvant or&#xD;
             for metastatic disease&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior hormonal therapy&#xD;
&#xD;
          -  Prior exogenous hormonal therapy for stage IV disease and/or as adjuvant therapy&#xD;
             allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  Prior localized radiotherapy allowed if no influence on the signal measurable lesion&#xD;
&#xD;
          -  Concurrent localized radiotherapy allowed if no influence on the signal measurable&#xD;
             lesion&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior major surgery and recovered&#xD;
&#xD;
          -  At least 2 weeks since prior minor surgery and recovered&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chau T. Dang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2003</verification_date>
  <study_first_submitted>October 4, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

